New ALS drug trial aims to tame inflammation
Disease control
Not yet recruiting
This early-phase trial tests an oral drug, Kamlanoflast, in 40 people with ALS. Over 24 weeks, researchers will check safety, tolerability, and whether the drug reduces inflammation and slows decline in function. It is not yet recruiting.
Phase: PHASE1, PHASE2 • Sponsor: Inflammasome Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC